Is MDG1.DE stock a buy after the pre-market drop?

The drop creates a speculative oversold bounce setup. Consider a small position with a stop under **€0.11**. Confirm volume-supported recovery above **€0.15** before adding exposure.

What are realistic near-term price targets for MDG1.DE stock?

Meyka AI models list a near-term relief target of **€0.30** and a 12-month scenario of **€0.80**. These are projections, not guarantees, and assume positive catalyst flow.

How does Medigene’s balance sheet affect the MDG1.DE stock outlook?

Medigene has **€1.36** cash per share and a current ratio of **2.53**, which supports short-term liquidity. Negative operating cash flow and EPS require monitoring of funding needs.

What technical signals matter for an oversold bounce in MDG1.DE stock?

Watch relative volume, a close back above **€0.15**, and follow-through toward **€0.30**. Failure to hold **€0.11** risks deeper downside and invalidates the bounce trade.

DE Stocks

MDG1.DE Medigene AG XETRA -27% pre-market 12 Feb 2026: Oversold bounce risk-reward

ByDanny Kontos February 12, 2026February 12, 2026

The MDG1.DE stock is trading pre-market at €0.13, after a heavy intraday sell-off of -27.64% on volume of 189,470 shares. This drop pushed the share price toward the year low of €0.11, creating an oversold bounce setup in XETRA trading in Germany. Short-term traders should watch the spike in relative volume (4.39x) and the gap below the 50-day average of €1.41. We outline technical triggers, balance-sheet context, and model-based price targets for an informed entry in this high-volatility biotech name.